M H Wauben - JoVE Visualize

Showing results (11-20 of 33) with videos related to

Pageof 4

Sort By:

Journal of Autoimmunity|April 1, 1992

Towards peptide immunotherapy in rheumatoid arthritis: competitor-modulator conceptM H Wauben, C J Boog, R van der Zee, et al.

Biologicals : Journal of the International Association of Biological Standardization|February 20, 2002

Structure-based design and evaluation of MHC class II binding peptidesE C de Haan, M H Wauben, M C Grosfeld-Stulemeyer, et al.

Immunogenetics|August 15, 2000

Selection of T-cell epitopes from foot-and-mouth disease virus reflects the binding affinity to different cattle MHC class II moleculesA Haghparast, M H Wauben, M C Grosfeld-Stulemeyer, et al.

European Journal of Immunology|May 1, 1994

Inhibition of entire myelin basic protein-induced experimental autoimmune encephalomyelitis in Lewis rats by major histocompatibility complex class II-binding competitor peptidesM H Wauben, A Kozhich, I Joosten, et al.

Journal of Immunology (Baltimore, Md. : 1950)|December 20, 2000

The efficacy of immunotherapy in an experimental murine model of allergic asthma is related to the strength and site of T cell activation during immunotherapyE M Janssen, A J van Oosterhout, F P Nijkamp, et al.

Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1994

Inhibition of experimental autoimmune encephalomyelitis by MHC class II binding competitor peptides depends on the relative MHC binding affinity of the disease-inducing peptideM H Wauben, I Joosten, A Schlief, et al.

Pharmaceutical Research|April 1, 1999

Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activationA J van Rensen, M H Wauben, M C Grosfeld-Stulemeyer, et al.

The Journal of Experimental Medicine|September 1, 1992

Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking aloneM H Wauben, C J Boog, R van der Zee, et al.

International Immunology|December 1, 2000

Nasal application of a naturally processed and presented T cell epitope derived from TCR AV11 protects against adjuvant arthritisE A van Tienhoven, C P Broeren, A Noordzij, et al.

Journal of Immunology (Baltimore, Md. : 1950)|November 9, 2000

T cell reactivity to heat shock protein 60 in diabetes-susceptible and genetically protected nonobese diabetic mice is associated with a protective cytokine profileA G van Halteren, B Mosselman, B O Roep, et al.

Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:

Pageof 4

Journal of Autoimmunity|April 1, 1992

Towards peptide immunotherapy in rheumatoid arthritis: competitor-modulator conceptM H Wauben, C J Boog, R van der Zee, et al.

Biologicals : Journal of the International Association of Biological Standardization|February 20, 2002

Structure-based design and evaluation of MHC class II binding peptidesE C de Haan, M H Wauben, M C Grosfeld-Stulemeyer, et al.

Immunogenetics|August 15, 2000

Selection of T-cell epitopes from foot-and-mouth disease virus reflects the binding affinity to different cattle MHC class II moleculesA Haghparast, M H Wauben, M C Grosfeld-Stulemeyer, et al.

European Journal of Immunology|May 1, 1994

Inhibition of entire myelin basic protein-induced experimental autoimmune encephalomyelitis in Lewis rats by major histocompatibility complex class II-binding competitor peptidesM H Wauben, A Kozhich, I Joosten, et al.

Journal of Immunology (Baltimore, Md. : 1950)|December 20, 2000

The efficacy of immunotherapy in an experimental murine model of allergic asthma is related to the strength and site of T cell activation during immunotherapyE M Janssen, A J van Oosterhout, F P Nijkamp, et al.

Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1994

Inhibition of experimental autoimmune encephalomyelitis by MHC class II binding competitor peptides depends on the relative MHC binding affinity of the disease-inducing peptideM H Wauben, I Joosten, A Schlief, et al.

Pharmaceutical Research|April 1, 1999

Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activationA J van Rensen, M H Wauben, M C Grosfeld-Stulemeyer, et al.

The Journal of Experimental Medicine|September 1, 1992

Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking aloneM H Wauben, C J Boog, R van der Zee, et al.

International Immunology|December 1, 2000

Nasal application of a naturally processed and presented T cell epitope derived from TCR AV11 protects against adjuvant arthritisE A van Tienhoven, C P Broeren, A Noordzij, et al.

Journal of Immunology (Baltimore, Md. : 1950)|November 9, 2000

T cell reactivity to heat shock protein 60 in diabetes-susceptible and genetically protected nonobese diabetic mice is associated with a protective cytokine profileA G van Halteren, B Mosselman, B O Roep, et al.

Pageof 4